Vis enkel innførsel

dc.contributor.authorBrede, Jostein Rødseth
dc.contributor.authorSkulberg, Arne Kristian
dc.contributor.authorRehn, Marius
dc.contributor.authorThorsen, Kjetil
dc.contributor.authorKlepstad, Pål
dc.contributor.authorTylleskär, Ida
dc.contributor.authorFarbu, Bjørn
dc.contributor.authorDale, Jostein
dc.contributor.authorNordseth, Trond
dc.contributor.authorWiseth, Rune
dc.contributor.authorKrüger, Andreas Jørstad
dc.date.accessioned2021-08-26T14:06:12Z
dc.date.available2021-08-26T14:06:12Z
dc.date.created2021-08-24T14:39:47Z
dc.date.issued2021-07
dc.identifier.citationBrede, J.R., Skulberg, A.K., Rehn, M. et al. (2021) REBOARREST, resuscitative endovascular balloon occlusion of the aorta in non-traumatic out-of-hospital cardiac arrest: a study protocol for a randomised, parallel group, clinical multicentre trial. Trials, 22:511, 1-9.en_US
dc.identifier.issn1745-6215
dc.identifier.urihttps://hdl.handle.net/11250/2771430
dc.description.abstractBackground Survival after out-of-hospital cardiac arrest (OHCA) is poor and dependent on high-quality cardiopulmonary resuscitation. Resuscitative endovascular balloon occlusion of the aorta (REBOA) may be advantageous in non-traumatic OHCA due to the potential benefit of redistributing the cardiac output to organs proximal to the aortic occlusion. This theory is supported by data from both preclinical studies and human case reports. Methods This multicentre trial will enrol 200 adult patients, who will be randomised in a 1:1 ratio to either a control group that receives advanced cardiovascular life support (ACLS) or an intervention group that receives ACLS and REBOA. The primary endpoint will be the proportion of patients who achieve return of spontaneous circulation with a duration of at least 20 min. The secondary objectives of this trial are to measure the proportion of patients surviving to 30 days with good neurological status, to describe the haemodynamic physiology of aortic occlusion during ACLS, and to document adverse events. Discussion Results from this study will assess the efficacy and safety of REBOA as an adjunctive treatment for non-traumatic OHCA. This novel use of REBOA may contribute to improve treatment for this patient cohort.en_US
dc.language.isoengen_US
dc.publisherBioMed Centralen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectkardiologien_US
dc.subjecthjerteinfarkten_US
dc.titleREBOARREST, resuscitative endovascular balloon occlusion of the aorta in non-traumatic out-of-hospital cardiac arrest: a study protocol for a randomised, parallel group, clinical multicentre trialen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© The Author(s). 2021en_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771en_US
dc.source.pagenumber1-9en_US
dc.source.volume22en_US
dc.source.journalTrialsen_US
dc.source.issue1en_US
dc.identifier.doi10.1186/s13063-021-05477-1
dc.identifier.cristin1928378
dc.source.articlenumber511 (2021)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal